Primary Humoral Immunodeficiency
BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of patients with primary humoral immunodeficiency (PI).
This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
DOSAGE AND ADMINISTRATION
For Intravenous Use Only
Preparation and Handling
- BIVIGAM is a clear or slightly opalescent, colorless to pale yellow solution. Inspect BIVIGAM visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or turbid, or contains particulate matter.
- Allow refrigerated product to come to room temperature before use.
- Do not freeze or heat. Do not use any solution that has been frozen or heated.
- DO NOT SHAKE.
- Do not mix BIVIGAM with other IGIV products or other intravenous medications. If large doses of BIVIGAM are to be administered, several vials may be pooled using aseptic technique into sterile infusion bags and infused.
- Do not dilute BIVIGAM.
- BIVIGAM contains no preservatives. BIVIGAM vial is for single use only. Any vial of BIVIGAM that has been entered should be used promptly and any unused portion should be discarded immediately. Do not reuse or save for future use.
- Maintain BIVIGAM at room temperature during administration.
- Do not use after expiration date.
As there are significant differences in the half-life of IgG among patients with primary humoral immunodeficiency, the frequency and amount of immunoglobulin therapy may vary from patient to patient. The proper amount can be determined by monitoring clinical response.
The recommended dose of BIVIGAM for replacement therapy in primary humoral immunodeficiency (PI) is 300 to 800 mg/kg body weight administered every 3 to 4 weeks. The dosage may be adjusted over time to achieve the desired trough levels and clinical response.
BIVIGAM dose adjustments may be required in patients who fail to maintain trough total IgG concentrations of at least 500 mg/dL with a target of 600 mg/dL. Starting with the second infusion, the dose will be adjusted proportionally, targeting a trough of ≥ 600 mg/dL, based on the previous trough and the associated dose.
It has been reported that the frequency of adverse drug reactions to IGIV increases with the infusion rate. Initial infusion rates should be slow. If there are no adverse drug reactions, the infusion rate for subsequent infusions can be slowly increased to the maximum rate. For patients experiencing adverse drug reactions, it is advisable to reduce the infusion rate in subsequent infusions.
Table 1: Recommended Infusion Rates for BIVIGAM
|Indication||Initial Infusion Rate (for first 10 minutes)||Maintenance Infusion Rate (if tolerated)|
|PI||0.5 mg/kg/min(0.005 mL/kg/min)||Increase every 20 minutes (if tolerated) by 0.8 mg/kg/min up to 6 mg/kg/min.|
Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.
Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer BIVIGAM at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates (see BOXED WARNING, WARNINGS AND PRECAUTIONS).
Dosage Forms And Strengths
BIVIGAM is a liquid solution containing 10% IgG (100 mg/mL) for intravenous infusion.
Storage And Handling
BIVIGAM is supplied in a single-use, tamper-evident vial. The components used in the packaging for BIVIGAM are latex free.
BIVIGAM is supplied in the following sizes:
|NDC Number||Size||Grams Protein|
Refrigerate between 2 to 8°C (36 to 46°F).
Special Precautions for Storage
Do not freeze or heat. Do not use any solutions that have been frozen or heated.
Allow refrigerated product to come to room temperature before use.
Do not use after expiration date.
BIVIGAM may be stored until expiration date on vial packaging at 2 to 8°C (36 to 46°F).
Do not dilute.
BIVIGAM should be infused using a separate line by itself, without mixing with other intravenous fluids or medications the patient may be receiving.
Manufacturer: Biotest Pharmaceuticals Corporation, Boca Raton, FL 33487. USA. Issued: April 2012This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/28/2013
Additional Bivigam Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.